-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Undetectable antibodies improve after a third dose of the coronavirus (COVID-19) vaccine in patients with hematological malignancies, a new study has found
People with lymphoma have deficiencies in their immune systems that limit their response to vaccinations
The prospective observational study, called PROSECO, was funded by the UK Blood Cancer Vaccine Research Collaboration and published in the journal Nature Cancer
Dr Sean Lim, Associate Professor of Haematology Oncology at the University of Southampton, explained: "Despite the gradual lifting of restrictions on COVID-19 globally, a cloud of gloom hangs over immunosuppressed patients as they may fail to develop protective immunity following vaccination.
Dr.
The purpose of the study was to assess the strength of the immune system's response to the vaccine and help predict the vaccine's effectiveness in lymphoma patients
The results showed that more than half of patients treated for cancer had no detectable antibody levels after the second dose of the vaccine, but about two-thirds had detectable T-cell responses
"We found a good correlation between antibody levels in blood samples and how well those antibodies blocked the binding of the virus to the ACE2 protein," said Dr.
For patients with suppressed immune systems, the key question is whether there is an association between antibody and cellular responses and the risk of COVID-19 infection, hospitalization, and death
Original text retrieval
Lim, SH, Stuart, B.
